1. Efficacy and safety of direct-acting antiviral agents when combined with secukinumab
- Author
-
Nuria Miserachs-Aranda, Inmaculada Torre-Lloverás, Virginia Martínez-Santana, Ruben del Río-Gil, Esther Rodriguez-Murphy, and Alex Smithson
- Subjects
Ledipasvir ,medicine.medical_specialty ,Sofosbuvir ,Autoimmune diseases ,Case Report ,Drug interactions ,Virus ,030207 dermatology & venereal diseases ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Pharmacotherapy ,Immune system ,Psoriasis ,Internal medicine ,medicine ,General Pharmacology, Toxicology and Pharmaceutics ,Interaccions dels medicaments ,030203 arthritis & rheumatology ,Malalties autoimmunitàries ,business.industry ,Hepatology ,medicine.disease ,Hepatitis C ,chemistry ,Immunology ,Secukinumab ,business ,medicine.drug - Abstract
Background The interference in the immune response induced by biological disease-modifying antirheumatic drugs (bDMARDs) increases the risk of reactivation of infections. Treatment of patients with chronic hepatitis C virus (HCV) infection and psoriasis is complex. The efficacy and safety of the new direct-acting antiviral agents (DAA) when combined with bDMARDs remain unknown. Case report We present a case of a 44-year-old Caucasian man affected with psoriasis and HCV infection. Throughout the course of the psoriatic disease, this patient received several lines of treatment, including secukinumab, a new type of bDMARD. At the time of commencing secukinumab, new DAA agents (ledipasvir/sofosbuvir) were also initiated. At week 12 post-treatment, hepatitis C viral load was undetectable and the patient remained in remission of psoriasis. Conclusion This case report suggests that secukinumab is a therapeutic option in patients with psoriasis, particularly in those cases with HCV infection where treatment with DAA agents is warranted.
- Published
- 2017